Vonoprazan, New Drug for Acid Inhibition: Efficacy and Safety
Keywords:
peptic ulcers, complications of stomach ulcers, gastroesophageal reflux disease, H. pylori, vonoprazanAbstract
When discussing medications for the treatment of peptic ulcers, uncomplicated gastric ulcers, complications of gastric ulcers, or gastroesophageal reflux disease (GERD), the commonly used and widely accepted class of drugs is proton pump inhibitors (PPIs). However, there are some limitations and potential side effects associated with PPIs for certain patients. Currently, new classes of drugs are being developed, such as potassium-competitive acid blockers (P-CABs). vonoprazan (VZN) is a drug within the P-CABs category that was approved in Japan in 2014 and became available for use in Japan in 2015. It was approved in Thailand in 2018, for the treatment and prevention of conditions caused by excessive gastric acid secretion. VZN is primarily metabolized by CYP3A4, which differs from PPIs that are primarily metabolized by CYP2C19. Therefore, VZN can cause adverse effects in patients with abnormalities of CYP3A4. When comparing other aspects, VZN has several advantages, including acid resistance and a longer duration of action, as well as effectiveness in treating GERD. The effectiveness of VZN in triple therapy, used in combination with antibiotics to assess the eradication rate of Helicobacter pylori (H. pylori) and the treatment of gastric ulcers, has shown favorable results. Additionally, in patients who smoke, VZN does not affect the eradication rate of H. pylori and demonstrates safety with side effects comparable to those of PPIs.
References
Ban MC. Management of NSAIDs-induced gastrointestinal injury. 2009 [Cited Apr 2, 2024]. Available from: https://shorturl.at/KuFMg
Chitapanarak T. Prevention of peptic ulcers caused by NSAID use. Acid related diseases awareness series. 2017 [Cited Apr 2, 2024]. Available from: https://www.takeda.com/siteassets/media/th-th/gi/e-publication/pdf/pdf-ct-8.pdf
MAYO clinic. Peptic ulcer. 2022 [Cited Apr 1, 2024]. Available from: https://shorturl.at/Zi1Wy
Vilaisorn R. Peptic ulcer. Wongkarnpat. 2016 [Cited Apr 2, 2024]. Available from: https://www.takeda.com/siteassets/media/th-th/gi/e-publication/pdf/pdf-ct-9.pdf
Lin KJ, García Rodríguez LA, Hernández-Díaz S. Systematic review of peptic ulcer disease incidence rates: do studies without validation provide reliable estimates? Pharmacoepidemiol Drug Saf 2011;20(7):718-28. doi:10.1002/pds.2153.
Grossi L, Ciccaglione AF, Marzio L. Esophagitis and its causes: Who is "guilty" when acid is found "not guilty"? World J Gastroenterol 2017;23(17):3011-6. doi:10.3748/wjg.v23.i17.3011.
Healthline. Can acid reflux cause life threatening complications?. 2020 [Cited Apr 2, 2024]. Available from: https://www.healthline.com/health/can-acid-reflux-kill-you
Scally B, Emberson JR, Spata E, Reith C, Davies K, Halls H, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol 2018;3(4):231-41. doi:10.1016/S2468-1253(18)30037-2.
Yibirin M, De Oliveira D, Valera R, Plitt AE, Lutgen S. Adverse effects associated with proton pump inhibitor use. Cureus 2021;13(1):e12759. doi:10.7759/cureus.12759.
Otake K, Sakurai Y, Nishida H, Fukui H, Tagawa Y, Yamasaki H, et al. Characteristics of the novel potassium-competitive acid blocker vonoprazan fumarate (TAK-438). Adv Ther 2016;33(7):1140-57. doi:10.1007/s12325-016-0345-2.
Dai Y, Liu B, Shen X, Huang L. Progress in the study of vonoprazan fumarate vs. proton pump inhibitors in the treatment of gastroesophageal reflux disease. Yangtza Med 2023;7(2):95-104.
Continuing Education Center for Pharmaceutical Sciences, Pharmacy Council. Vonoprazan in the treatment of gastroesophageal reflux disease. 2024 [Cited Feb 20, 2024]. Available from: https://ccpe.pharmacycouncil.org/index.php?option=article_detail&subpage=article_detail&id=1171
Howden CW, Cook EE, Swallow E, Yang K, Guo H, Pelletier C, et al. Real-world outcomes associated with vonoprazan-based versus proton pump inhibitor-based therapy for Helicobacter pylori infection in Japan. Therap Adv Gastroenterol 2023;16:17562848231168714. doi:10.1177/17562848231168714.
Tassaneeyakul W. Pharmacogenetics. 2009. [Cited Apr 2,2024]. Available from: https://thaiscience.info/Journals/Article/SRMJ/10463826.pdf
Lexicomp. Lexi-drugs multinational / vonoprazan. 2024. [Cited Feb 20, 2024]. Available from: Lexicomp application.
Hori Y, Matsukawa J, Takeuchi T, Nishida H, Kajino M, Inatomi N. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther 2011;337(3):797-804. doi:10.1124/jpet.111.179556.
Jenkins H, Sakurai Y, Nishimura A, Okamoto H, Hibberd M, Jenkins R, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan). A novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 2015;41(7):636–48. doi:10.1111/apt.13121.
Shin JM, Inatomi N, Munson K, Strugatsky D, Tokhtaeva E, Vagin O, et al. Characterization of novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-Fluorophenyl)-1-(pyridine-3- ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther 2011;339(2):412–20. doi:10.1124/ jpet.111.185314.
Scot DR, Munson KB, Marcus EA, Lambrecht NW, Sachs G. The binding selectivity of vonoprazan (TAK-438) to the gastric H+ ,K+-ATPase. Aliment Pharmacol Ther 2015;42(11–12):1315–26. doi:10.1111/ apt.13414.
Yamasaki H, Kawaguchi N, Nonaka M, Takahashi J, Morohashi A, Hirabayashi H, et al. In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica 2017;47(12):1027–34. doi:10.1080/00498254.2016.1203505.
Yoneyama T, Teshima K, Jinno F, Kondo T, Asahi S. A validated simultaneous quantification method for vonoprazan (TAK-438F) and its 4 metabolites in human plasma by the liquid chromatographytandem mass spectrometry. J Chromatogr B Analyt Technol Biomed 2016;1015–1016:42–9. doi:10.1016/j.jchromb.2016.01.051.
Sakurai Y, Nishimura A, Kennedy G, Hibberd M, Jenkins R, Okamoto H, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male Japanese/ non-Japanese subjects. Clin Transl Gastroenterol 2015;6(6):e94. doi:10.1038/ctg.2015.18
Andersson K, Carlsson E. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther 2005;108(3):294-307. doi:10.1016/j.pharmthera.2005.05.005.
Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebocontrolled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998;12(11):1079-89. doi:10.1046/j.1365-2036.1998.00418.x.
Oshima T, Miwa H. Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases. J Neurogastroenterol Motil 2018;24(3):334-44. doi: 10.5056/jnm18029.
Sakurai Y, Mori Y, Okamoto H, Nishimura A, Komura E, Ariki T, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study. Aliment Pharmacol Ther 2015;42(6):719-30. doi:10.1111/apt.13325.
Arikawa Y, Nishida H, Kurasawa O, Hasuoka A, Hirase K, Inatomi N, et al. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassiumcompetitive acid blocker (P-CAB). J Med Chem 2012;55(9):4446-56. doi:10.1021/jm300318t
Hori Y, Imanishi A, Matsukawa J, Tsukimi Y, Nishida H, Arikawa Y, et al. 1-[5-(2-Fluorophenyl)- 1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther 2010;335(1):231-8. doi:10.1124/jpet.110.170274.
Kagami T, Sahara S, Ichikawa H, Uotani T, Yamade M, Sugimoto M, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther 2016;43(10):1048-59. doi:10.1111/apt.13588.
Sugano K. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Therap Adv Gastroenterol 2018;11:1756283X17745776. doi:10.1177/1756283X17745776.
Yang X, Li Y, Sun Y, Zhang M, Guo C, Mirza IA, et al. Vonoprazan: a novel and potent alternative in the treatment of acid-related diseases. Dig Dis Sci 2018;63(2):302-11. doi:10.1007/s10620-017-4866-6.
Kawai T, Oda K, Funao N, Nishimura A, Matsumoto Y, Mizokami Y, et al. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut 2018;67(6):1033-41. doi:10.1136/gutjnl-2017-314852.
Mizokami Y, Oda K, Funao N, Nishimura A, Soen S, Kawai T, et al. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut 2018;67(6):1042-51. doi:10.1136/gutjnl-2017-314010.
Keeratichananont S. The dangers of helicobacter pylori infection in the stomach and how to treat it. [Cited 2024 Mar 27]. Available from: https://wongkarnpat.com/upfilesym/Eisai 4p.pdf
Sakurai K, Suda H, Ido Y, Takeichi T, Okuda A, Hasuda K, et al. Comparative study: vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy. World J Gastroenterol 2017;23(4):668-75. doi:10.3748/wjg.v23.i4.668.
Lyu QJ, Pu QH, Zhong XF, Zhang J. Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis of randomized clinical trials. Biomed Res Int 2019;2019:9781212. doi:10.1155/2019/9781212.
Shehryar M, Ahmad RU, Kareem HK, Khan L, Ashraf MF, Hassan A, Saeed S, Tareen HK, Nazir DA, Ashraf MA. Efficacy, safety and cost-effectiveness of vonoprazan vs Proton Pump Inhibitors in reflux disorders and H. pylori eradication: a literature review. Ann Med Surg (Lond) 2022;82:104760. doi:10.1016/j.amsu.2022.104760.
Cheng Y, Liu J, Tan X,Dai Y, Xie C, Li X, et al. Direct comparison of the efficacy and safety of vonoprazan versus proton-pump inhibitors for gastroesophageal reflux disease: a systematic review and meta-analysis. Dig Dis Sci 2021;66(1):19–28. doi:10.1007/s10620-020-06141-5
Dong SQ, Singh TP, Wei X, Yao H, Wang HL. Review: a Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion? Helicobacter 2017;22(6). doi:10.1111/hel.12438.
Echizen H. The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 2016;55(4):409-18. doi:10.1007/s40262-015-0326-7.
Miftahussurur M, Pratama Putra B, Yamaoka Y. The potential benefits of vonoprazan as Helicobacter pylori infection therapy. Pharmaceuticals (Basel) 2020;13(10):276. doi:10.3390/ph13100276.
Shinozaki S, Kobayashi Y, Osawa H, Sakamoto H, Hayashi Y, Lefor AK, et al. Effectiveness and safety of vonoprazan versus proton pump inhibitors for second-line Helicobacter pylori eradication therapy: systematic review and meta-analysis. Digestion 2021;102(3):319-25. doi:10.1159/000504939.
Otyepka M, Berka K, Anzenbacher P. Is there a relationship between the substrate preferences and structural flexibility of cytochromes P450? Curr Drug Metab 2012;13(2):130-42. doi:10.2174/138920012798918372.
Sevrioukova IF, Poulos TL. Understanding the mechanism of cytochrome P450 3A4: recent advances and remaining problems. Dalton Trans 2013;42(9):3116-26. doi:10.1039/c2dt31833d.
Dundee J. The mechanism of oxygen binding, cooperativity in hemoglobin: a tutorial. [Cited Mar 23, 2024]. Available from: https://community.middlebury.edu/~sontum/chemistry/students/dundee/index.html
Nakatani K, Ishikawa H, Aono S, Mizutani Y. Identification of essential histidine residues involved in heme binding and Hemozoin formation in heme detoxification protein from Plasmodium falciparum. Sci Rep 2014;4:6137. doi:10.1038/srep06137.
Seger ST, Rydberg P, Olsen L. Mechanism of the N-hydroxylation of primary and secondary amines by cytochrome P450. Chem Res Toxicol 2015;28(4):597-603. doi:10.1021/tx500371a.
Wang Y, Wang C, Wang S, Zhou Q, Dai D, Shi J, et al. Cytochrome P450-based drug-drug interactions of vonoprazan in vitro and in vivo. Front Pharmacol 2020;11:53. doi:10.3389/fphar.2020.00053.
Manimekalai K, Codi RS, Veererathinakumar NK, Ananthy V. Potassium-competitive acid blocker: a newer target in the treatment of acid peptic disorder. SBV Basic Clinical and Applied Health Science 2023;6(2): 33–8. doi:10.5005/jp-journals-10082-03182
Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Ailment Pharmacol Ther 2017;46(2):106–14. doi:10.1111/apt.14130.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Srinagarind Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
